<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9135">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00772772</url>
  </required_header>
  <id_info>
    <org_study_id>MAP-0626</org_study_id>
    <nct_id>NCT00772772</nct_id>
  </id_info>
  <brief_title>Vitamin D Repletion in Chronic Kidney Disease</brief_title>
  <official_title>The Effect of Vitamin D3 Repletion in Chronic Kidney Disease Stage 3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rockefeller University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The reason for doing this research is that people with kidney disease often suffer from
      heart disease. Why this happens is not fully known. A possible cause may be high blood
      levels of a substance made by bacteria called &quot;endotoxin&quot;. The blood levels of this
      substance are high in people with medium-level kidney disease.

      We want to know if replacing normal amounts of Vitamin D can help lower the levels of this
      substance. We also want to know if replacing normal amounts of Vitamin D is associated with
      other changes that may help heart disease. We hope that our research will help figure out if
      levels of this substance can be lowered by replacing normal amounts of Vitamin D. Normal
      subjects are enrolled to have a 'control' set for comparison purposes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Your participation in this study requires:

        -  4 visits to the outpatient clinic (including 1 screening visit)

        -  Providing a blood sample (less than 5 tablespoons) and a urine sample at each visit

        -  Taking a test to measure how leaky your gut is. This test requires that you drink a
           small amount of liquid (about 4 ounces) and then collect your urine for 6 hours after
           drinking the liquid.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Endotoxin Activity</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Endotoxin Activity as measured by the Endotoxin Activity Assay. This measurement was made at baseline and after 8 weeks of therapy with Vitamin D3. The measurement of the assay is unitless. It is not based on an absolute amount of endotoxin, but rather the proportion of the theoretical maximal response of the patient and ranges from 0 (lowest) to 1 (highest).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>after 8 weeks of vitamin D therapy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal Permeability</measure>
    <time_frame>after 8 weeks of vitamin D therapy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nuclear Magnetic Resonance (NMR) Lipoprotein Profile</measure>
    <time_frame>after 8 weeks of vitamin D therapy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25-hydroxy Vitamin D (25-OH Vitamin D)</measure>
    <time_frame>after 8 weeks of vitamin D therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>25-OH Vitamin D levels were measured in patients with chronic kidney disease at baseline and after 8 weeks of treatment with Vitamin D3 30000 units weekly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1, 25-OH Vitamin D</measure>
    <time_frame>after 8 weeks of vitamin D therapy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D3 30,000 international units orally per week for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>2 single oral dose of Vitamin D3 30,000 international units and 8 weeks supply of Vitamin D3 (10,000 IU tablets, 3 pills to be taken by mouth as one dose weekly)</description>
    <arm_group_label>Vitamin D3</arm_group_label>
    <other_name>Vitamin D</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion Criteria for Healthy volunteers

          -  Males and post-menopausal females, between the age of 50 -80.

          -  Vitamin D 25-OH level less than 20 ng/ml

        Inclusion Criteria for Medium-level Kidney Function volunteers

          -  Males and post-menopausal females, between the age of 50 -80.

          -  Chronic kidney disease stage 3

          -  Vitamin D 25-OH level less than 20 ng/ml

        Exclusion Criteria:

          -  Serum calcium level &gt;10.5 mg/dl

          -  Serum phosphorus level &gt; 5.5 mg/dl

          -  Serum PTH level &lt; 35 pg/ml

          -  Active infection including HIV, Hepatitis B or C

          -  History of recent acute infection ( within 1 month)

          -  Gastrointestinal disease resulting in significant GI dysfunction or malabsorption

          -  Hgb&lt; 10 g/dL

          -  Current use of Coumadin

          -  Current use of Vitamin D &gt;400 IU/day

          -  Current use of systemic steroids or other immunosuppressants

          -  History of malignancy not in remission (&gt;6 months)

          -  History of current ethanol abuse or illicit drug use

          -  History of significant emotional disorder within the past 5 years

          -  Participation in an investigational drug study within one month of screening

          -  Have any other condition, which in the opinion of the investigator, should prohibit
             the participation in the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manish Ponda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rockefeller University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rockefeller University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <lastchanged_date>January 6, 2015</lastchanged_date>
  <firstreceived_date>October 13, 2008</firstreceived_date>
  <firstreceived_results_date>March 10, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rockefeller University</investigator_affiliation>
    <investigator_full_name>Manish Ponda</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Investigation</investigator_title>
  </responsible_party>
  <keyword>Vitamin D3 repletion</keyword>
  <keyword>levels of endotoxin</keyword>
  <keyword>intestinal permeability</keyword>
  <keyword>accelerated atherosclerosis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vitamin D3</title>
          <description>Vitamin D3 30,000 units PO weekly for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin D3</title>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="61" spread="7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Endotoxin Activity</title>
        <description>Endotoxin Activity as measured by the Endotoxin Activity Assay. This measurement was made at baseline and after 8 weeks of therapy with Vitamin D3. The measurement of the assay is unitless. It is not based on an absolute amount of endotoxin, but rather the proportion of the theoretical maximal response of the patient and ranges from 0 (lowest) to 1 (highest).</description>
        <time_frame>baseline and 8 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per protocol. Result is expressed as change in endotoxin activity with therapy</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With Chronic Kidney Disease (CKD)</title>
            <description>CKD patients who were Vitamin D deficient and received Vitamin D3 repletion</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Endotoxin Activity</title>
            <description>Endotoxin Activity as measured by the Endotoxin Activity Assay. This measurement was made at baseline and after 8 weeks of therapy with Vitamin D3. The measurement of the assay is unitless. It is not based on an absolute amount of endotoxin, but rather the proportion of the theoretical maximal response of the patient and ranges from 0 (lowest) to 1 (highest).</description>
            <units>EA units</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-.057" spread=".018"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Pressure</title>
        <time_frame>after 8 weeks of vitamin D therapy</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intestinal Permeability</title>
        <time_frame>after 8 weeks of vitamin D therapy</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nuclear Magnetic Resonance (NMR) Lipoprotein Profile</title>
        <time_frame>after 8 weeks of vitamin D therapy</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>25-hydroxy Vitamin D (25-OH Vitamin D)</title>
        <description>25-OH Vitamin D levels were measured in patients with chronic kidney disease at baseline and after 8 weeks of treatment with Vitamin D3 30000 units weekly.</description>
        <time_frame>after 8 weeks of vitamin D therapy</time_frame>
        <safety_issue>No</safety_issue>
        <population>Patients with chronic kidney disease had 25-OH vitamin D levels measured at baseline and after 8 weeks of Vitamin D3 therapy. Analysis was per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>CKD Patients</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>25-hydroxy Vitamin D (25-OH Vitamin D)</title>
            <description>25-OH Vitamin D levels were measured in patients with chronic kidney disease at baseline and after 8 weeks of treatment with Vitamin D3 30000 units weekly.</description>
            <units>ng/ml</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="37.4" spread="3.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1, 25-OH Vitamin D</title>
        <time_frame>after 8 weeks of vitamin D therapy</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vitamin D3</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematologic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mansih Ponda</name_or_title>
      <organization>The Rockefeller University</organization>
      <phone>212-327-7631</phone>
      <email>mponda@rockefeller.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
